As Charles River And WuXi PharmaTech Count Down To Shareholder Votes On Proposed Merger, Research Analysts Predict Defeat
This article was originally published in The Pink Sheet Daily
Executive Summary
Charles River says the CRO's major pharma clients support the deal.
You may also be interested in...
Charles River, WuXi PharmaTech CEOs Issue Joint Appeal For Shareholder Support For Deal
BEIJING - The heads of the Massachusetts-based Charles River Laboratories and the Shanghai-headquartered WuXi PharmaTech issued a joint appeal calling for shareholders to rally in support of the proposed union of the two contract research organizations during near-simultaneous votes four weeks from now
Impromptu Objections Filed With SEC Could Threaten Charles River's Proposed Merger With China's Leading CRO
BEIJING - A New York-headquartered money management outfit that is the largest shareholder in Charles River Laboratories International has unexpectedly thrown up a potential blockade in the drug research firm's $1.6 billion proposal to acquire China's WuXi PharmaTech
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.